What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline

Livermore, David M.; Warner, Marina; Mushtaq, Shazad; Doumith, Michel; Zhang, Jiancheng; Woodford, Neil

doi:10.1016/j.ijantimicag.2011.01.012

Cited by 300 publications

(204 citation statements)

References 17 publications

Supporting

Mentioning

175

Contrasting

Unclassified

Order By: Relevance

“…As a consequence, clinicians will most likely prescribe other antimicrobial classes. As the amount of antibiotic used and the development of resistance are generally linked, increased reports of Enterobacteriaceae resistant to third-generation cephalosporins and carbapenems may cause greater usage of other antibiotics and changes in antibiograms [13,14]. Further clinical studies are required to determine the long-term effects on the antimicrobial stewardship policy and the trends in antibiotic resistance.…”

Section: Discussionmentioning

confidence: 99%

Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints

Liu

Shi

Tung

et al. 2014

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: The Clinical and Laboratory Standards Institute (CLSI) updated its antimicrobial susceptibility testing interpretation criteria for Enterobacteriaceae. This study assessed the effects of clinical breakpoint changes in the CLSI 2009 to 2012 guidelines on antibiotic susceptibility testing reports. Methodology: In total, 2,076 non-duplicate clinical isolates of Enterobacteriaceae were analyzed. The disk diffusion method was used for susceptibility testing. The CLSI 2009-12 clinical breakpoints were applied to determine susceptibility of cefotaxime and ertapenem. Combined-disk testing was used for phenotypic confirmation of extended-spectrum beta-lactamase (ESBL) production. Results: In total, Enterobacteriaceae resistance rates to cefotaxime increased from 13.1% using the CLSI 2009 guidelines to 23.6% with the CLSI 2010-12 guidelines, and the resistance rates to ertapenem were 0.4%, 1.0% and 0.8% with CLSI 2009, 2011 and 2012, respectively. Based on the 2010-12 CLSI criteria, all ESBL-producing Escherichia coli and Klebsiella pneumoniae were resistant to cefotaxime. Marked differences in susceptibility to ertapenem between the 2009 CLSI criteria and 2012-12 CLSI criteria were noted in ESBL-producing K. pneumoniae. Conclusions: Breakpoints changes in the updated CLSI guidelines resulted in higher resistance rates to cefotaxime and ertapenem. In addition, the effects were different in individual Enterobacteriaceae species. As a result, clinicians may opt to use alternative antimicrobial agents. Upon implementation of the newer CLSI guidelines, laboratories should be aware of the possible consequences and closely monitor the effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints

Liu

Shi

Tung

et al. 2014

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…In countries such as the United States, Israel,Germany and Greece, carbapenemase-producing Enterobacteriaceae (CPE) had emerged and the dissemination of these multidrug-resistant pathogens had become a problem in clinical care of patients and in public health [4][5][6][7] . Invasive infections with these organisms have been associated with high rates of morbidity and mortality, due to their resistance to most available antimicrobial agents [8][9][10] . Patients who are hospitalized for prolonged periods and those with severe underlying disease are at high risk of acquiring these types of pathogens 11 .…”

Section: Introductionmentioning

confidence: 99%

Characteristics and management of Enterobacteriaceae harboring IMP-4 or IMP-8 carbapenemase in a tertiary hospital

Pang¹,

Jia²,

Song³

et al. 2016

Afr H. Sci.

View full text Add to dashboard Cite

Background: The emergence of Enterobacteriaceae harboring IMP-4 or IMP-8 carbapenemases is rare. We report an occurrence of Enterobacteriaceae harboring IMP-4 or IMP-8 carbapenemases in a Chinese tertiary care hospital from November 2010 to December 2012. Methods: The clinical characteristics of 30 patients were described. The genetic relationship of isolates was determined by pulsed-field gel electrophoresis (PFGE). Carbapenemases were detected by modified Hodge test (MHT) and polymerase chain reactions (PCRs). Amplicons were sequenced and blasted to determine the genotype. Results: Most infected patients were from intensive care unit and had complex and serious underlying illnesses requiring mechanical ventilation. PFGE revealed that Klebsiella pneumoniae showed two major PFGE types. Two Klebsiella oxytoca had an indistinguishable PFGE pattern, while four Enterobacter cloacae were different strains. The sequencing studies showed Enterobacteriaceae harboring IMP-4 or IMP-8 carbapenemase in the 23 infected patients. The majority of patients had infections with the carbapenemase-producing Enterobacteriaceae (CPE) strain, most were successfully treated with a range of antibiotics and discharged. Conclusion: It is important to maintain a high index of suspicion to screen for carbapenemase-producing Enterobacteriaceae strains. Rapid identification of these strains and implementation of stringent procedures are the key to prevent major outbreaks in a hospital setting.

show abstract

“…[30]. Similarly, contemporary isolates from Greece were only susceptible in 64% of cases for XDR K. pneumoniae and 44% for A. baumannii [31].…”

Section: Tigecyclinementioning

confidence: 95%

Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012

Tambyah

Hara

Daikos

et al. 2013

Journal of Global Antimicrobial Resistance

View full text Add to dashboard Cite

What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline

Cited by 300 publications

References 17 publications

Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints

Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints

Characteristics and management of Enterobacteriaceae harboring IMP-4 or IMP-8 carbapenemase in a tertiary hospital

Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012

Contact Info

Product

Resources

About